Zymeworks Inc. current report, 21 October 2022

Full document

Business Context and Reporting Period

Zymeworks Inc. filed this Form 8-K on October 21, 2022, reporting changes to its at-the-market equity offering arrangements. The filing does not report quarterly or annual operating results.

Material Agreement and Financing Terms

  • Zymeworks entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell common stock from time to time through an at-the-market offering.
  • The aggregate offering capacity is subject to the maximum amount registered under the applicable prospectus supplement; the filing text does not provide a clear dollar amount.
  • The company is not obligated to sell any shares.
  • Jefferies may sell shares on the New York Stock Exchange or another permitted trading market based on company instructions.
  • Jefferies will receive a commission of up to 3.0% of gross proceeds from shares sold.
  • The agreement includes customary indemnification and contribution provisions and may be terminated by either party under its terms.

Termination of Prior Agreement

Zymeworks BC Inc., the company’s subsidiary, and Jefferies mutually terminated their November 5, 2019 at-the-market sales agreement, as amended. No Zymeworks BC common shares were sold under the prior agreement.

Financial Metrics, Liquidity, and Outlook

This filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity metrics, financial guidance, or operating forecasts. Any future equity sales could provide financing but may dilute existing shareholders; the amount and timing of sales are not specified.

Key Risks and Unusual Items

  • Future share sales are discretionary and depend on company instructions and market conditions.
  • Issuance of common stock could dilute existing holders and pressure the share price.
  • The filing’s agreement representations and warranties may have been qualified by nonpublic disclosures and should not be treated as comprehensive statements of current fact.

Facts Investors Should Verify

  • The maximum aggregate offering amount in the prospectus supplement and related registration statement.
  • Whether any shares have subsequently been sold under the new Sales Agreement and the net proceeds received.
  • The company’s cash runway, financing needs, and potential dilution in subsequent SEC filings.
  • The complete terms of the Sales Agreement, including termination provisions and selling restrictions.